2-(aminooxy)-2-phenylethanol | 6006-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(aminooxy)-2-phenylethanol
• 英文别名: O-(2-Hydroxy-1-phenyl-ethoxy)-hydroxylamin；O-(2-Hydroxy-1-phenyl-ethyl)-hydroxylamin；n-(2-Hydroxy-1-phenylaethyloxy)-amin；2-aminooxy-2-phenylethanol
• CAS: 6006-67-3
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: YKKNIHJQHDILIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(aminooxy)-2-phenylethanol 、 异氰酸苯酯 以 苯 为溶剂， 生成 1-Phenyl-3-< 1-phenyl-(2-phenylcarbamoyloxy)-aethoxy>-harnstoff
  参考文献：
  名称：

  Kliegel, Pharmazie, 1970, vol. 25, # 9, p. 525 - 529

  摘要：

  DOI：
• 作为产物：
  描述：

  α-溴苯乙酸乙酯 在 氢氧化钾 、 lithium aluminium tetrahydride 、 甘油 作用下， 以 乙醚 为溶剂， 生成 2-(aminooxy)-2-phenylethanol
  参考文献：
  名称：

  O，N-取代羟基胺。2. Mitteilung。O-（苯基烷基）-羟胺的合成与本征交换（Untersuchungenübersynthetische Arzneimitteln II）

  摘要：

  Es wirdüber合成，化学与物理化学化学反应，合成O-（苯基烷基）-羟胺胺。盐酸氢硼酸甘油酯，位于羟基苯并二苯并二恶英，C-Atome得到了保护，氢已被氨化，氨氮磷铵。Letztere wurden zum Teil气相色谱法和鉴定方法。分子式：A-（1-甲基-2-苯基-乙基）-羟基lamin-盐酸盐：氯化铵，丙苯酮（72％）和甲基苄基酮（28％）。O-（2-苯基-乙基）-羟基lamin-盐酸盐：氯化铵和2，5-二苯基-1，4-二恶烷；O-（1-甲基-2-苯基-乙基）-N-甲基-羟基lamin-盐酸盐：甲胺盐酸盐，丙炔酮（59.4％）和甲基-苄基酮（40.6％）；

  DOI：

  10.1002/hlca.19620450502

文献信息

• IDO inhibitors
  申请人：Mautino Mario

  公开号：US10047066B2

  公开（公告）日：2018-08-14

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供的方法包括：(a) 调节吲哚胺2,3-二氧化酶的活性，包括将吲哚胺2,3-二氧化酶与本文描述的某一方面中描述的化合物的调节有效量接触；(b) 治疗需要吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制的受试者，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(c) 治疗受益于吲哚胺-2,3-二氧化酶酶活性抑制的医疗状况，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(d) 增强抗癌治疗的有效性，包括给予抗癌药物和本文描述的某一方面中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；以及(f) 治疗与传染病相关的免疫抑制，例如HIV-I感染，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
  申请人：NEWLINK GENETICS

  公开号：WO2009073620A2

  公开（公告）日：2009-06-11

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
• O, N-substituierte Hydroxylamine. 2. Mitteilung. Synthese und Eigenschaften der O-(Phenylakyl)-hydroxylamine (Untersuchungen über synthetische Arzneimitteln II)
  作者：Bruno J. R. Nicolaus、Giuseppe Pagani、Emilio Testa

  DOI：10.1002/hlca.19620450502

  日期：——

  Es wird über Synthese, chemische und physikalisch-chemische Eigenschaften von O-(Phenylalkyl)-hydroxylaminen berichtet. Die Hydrochloride derjenigen Basen, in welchen die Hydroxylamingruppierung und der Phenylkern durch zwei C-Atome getrennt sind, sind merkwürdigerweise unbeständig und lagern sich spontan bei Zimmertemperatur zu einem Ammoniumsalz und stickstoffreien Verbindungen um. Letztere wurden

  Es wirdüber合成，化学与物理化学化学反应，合成O-（苯基烷基）-羟胺胺。盐酸氢硼酸甘油酯，位于羟基苯并二苯并二恶英，C-Atome得到了保护，氢已被氨化，氨氮磷铵。Letztere wurden zum Teil气相色谱法和鉴定方法。分子式：A-（1-甲基-2-苯基-乙基）-羟基lamin-盐酸盐：氯化铵，丙苯酮（72％）和甲基苄基酮（28％）。O-（2-苯基-乙基）-羟基lamin-盐酸盐：氯化铵和2，5-二苯基-1，4-二恶烷；O-（1-甲基-2-苯基-乙基）-N-甲基-羟基lamin-盐酸盐：甲胺盐酸盐，丙炔酮（59.4％）和甲基-苄基酮（40.6％）；